Bioxytran, Inc. (OTCQB:BIXT), a clinical-stage biotechnology company developing carbohydrate-based therapeutics, today ...
Low dose alnodesertib plus gemcitabine met the primary endpoint of progression-free survival (PFS) versus gemcitabine alone ...
An international, randomized, double-blind, placebo-controlled Phase III study—the largest of its kind for mpox—found that ...
Controlled study designed to confirm previous compelling efficacy with preliminary data expected by the end of 2026 Pelareorep-based treatment regimen recently granted Fast Track Designation in 2L ...
USA: Oral semaglutide may lower the risk of heart failure–related events in people with type 2 diabetes who already have heart failure, without increasing serious adverse events, a secondary analysis ...
A phase 2 study of response-guided neoadjuvant sacituzumab govitecan and pembrolizumab (SG/P) in patients with early-stage triple-negative breast cancer: Results from the NeoSTAR trial. This is an ...
Daiichi Sankyo announced that the first patient has been dosed in the global phase 3 TROPION-Lung17 trial. The study is evaluating DATROWAY in patients with locally advanced or metastatic nonsquamous ...
Utility of the 70-Gene MammaPrint Assay for Prediction of Benefit From Extended Letrozole Therapy in the NRG Oncology/NSABP B-42 Trial Patients with advanced lung cancer reporting at least moderate ...
Among six trials that analyzed outcomes for nearly 20,000 participants by sex, women lost an average of 10.88% (95% CI -14.76 to -7) of their baseline body weight on a GLP-1 agent, while men lost 6.8% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results